纳米载药系统在肝纤维化治疗中的作用进展  

Progress of Nanoparticles Drug Delivery System in the Treatment of Liver Fibrosis

作　　者：王灿 潘芝玲 夏帅 盛涛 张兵锋[1] WANG Can;PAN Zhi-ling;XIA Shuai;SHENG Tao;ZHANG Bing-feng(College of Chemistry and Bio engineering,Yichun University,Yichun 336000,China)

机构地区：[1]宜春学院化学与生物工程学院,江西宜春336000

出　　处：《宜春学院学报》2024年第6期24-27,共4页Journal of Yichun University

基　　金：江西省研究生创新专项资金项目(编号:YC2023-S977)。

摘　　要：肝纤维化是肝脏疾病早期出现的标志,急慢性肝脏损伤或炎症都可能导致肝纤维化,其发生在更为严重的肝硬化与肝癌阶段之前。然而对于肝纤维化,目前临床上尚未有较好的治疗方法与特异性药物。而纳米载体凭借材料本身的理化特性与对纳米载体表面进行功能化修饰,可以改善药物的代谢与分布,提高药物的靶向性,实现更好的治疗效果。本文总结了纳米载体在治疗肝纤维化过程中的应用,为构建安全有效的纳米载药系统,实现临床上肝纤维化的高效治疗提供理论依据。Liver fibrosis is a sign of early onset of liver disease.Acute and chronic liver injury or inflammation can lead to liver fibrosis,which already occurs before the more serious stages of cirrhosis and liver cancer.However,there are no better clinical treatments and specific drugs for liver fibrosis.Nanocarriers can improve drug metabolism and distribution,enhance drug targeting and achieve better therapeutic effects by virtue of the physical and chemical properties of the material itself and functional modification of the nanocarrier surface.This paper summarizes the application of nanocarriers in the treatment of liver fibrosis,and provides a theoretical basis for the construction of safe and effective nanoparticles drug delivery systems for the efficient treatment of liver fibrosis in the clinic.

关 键 词：纳米载药系统 肝纤维化 肝星状细胞 主动靶向 

分 类 号：R943[医药卫生—药剂学]